2026– date –
-
Carvykti: 5-year durable remission data for multiple myeloma
Rare Cancer News USA Overview New long-term clinical trial data from the CARTITUDE-2 study showed that 10 of 20 patients (50%) with hard-to-treat multiple myeloma remained alive and free from disease progression five years after a single... -
miv-cel CAR T-Cell: Kyverna’s 1-year benefit specs for SPS and MG
CGTlive® USA Overview Kyverna Therapeutics reported positive one-year data for mivocabtagene autoleucel (miv-cel), a CD19-directed CAR T-cell therapy, showing durable benefits in patients with Stiff Person Syndrome (SPS) and generalized ... -
AMT-130: uniQure’s 4-year Huntington’s disease progression data
pharmaphorum USA Overview uniQure announced updated four-year results from its Phase 1/2 study of ifezuntirgene inilparvovec (AMT-130) for Huntington's disease, showing a 'meaningful slowing of disease progression' in 12 patients. The ge... -
BAG3 Gene Therapy: UAB’s first Phase 1 trial timeline and specs
UAB News USA Overview The University of Alabama at Birmingham (UAB) has dosed the first patient globally in a Phase 1 gene therapy trial targeting BAG3 mutation-associated dilated cardiomyopathy (DCM). This pioneering first-in-human stud... -
CRISPR-Cas9: 1-year cholesterol reduction specs for lipid disorder
ScienceDaily (New England Journal of Medicine) USA Overview A Phase 1 clinical trial from Cleveland Clinic reported that a single infusion of a CRISPR-Cas9 gene-editing therapy led to sustained reductions in LDL cholesterol and triglycer... -
CRISPR CD33-Negative Stem Cells: WashU AML therapy explained
WashU Medicine (Nature Medicine) USA Overview Researchers at WashU Medicine successfully used CRISPR to remove CD33 from donor stem cells in a 30-patient trial, demonstrating that these edited cells engrafted and shielded healthy blood c... -
OPM Biosciences CHO Platform: 96% titer improvement specs
SelectScience UK Overview OPM Biosciences has expanded its OPM-CHO platform for biosimilar developers, launching a new Biosimilar Media Optimization Service and Sureness™ Biosimilar Platform. This service demonstrates an average titer im... -
N-1 Perfusion explained: 50% COGS reduction for BioProcess Tools
BioProcess Tools Unknown Overview A comparative analysis of upstream process intensification strategies revealed N-1 perfusion as a leading approach, reducing cost of goods sold (COGS) by 30-50% and increasing product titer by 85-100% wh... -
BioProcess Tools: 4-stage roadmap for 200,000L fermentation
BioProcess Tools USA Overview BioProcess Tools has unveiled a comprehensive four-stage scale-up strategy for precision fermentation, guiding processes from 10-liter lab scale to 200,000-liter commercial production over 3-6 years. This fr... -
MIT Microfluidic Device: 3D-printed specs for cancer detection
MIT News USA Overview MIT researchers have developed a 3D-printed microfluidic device for gentle, non-invasive collection of living cells from tissue. The device utilizes a vacuum seal and fluidic shear stress to detach viable cells, whi...
